Cargando…
Vascular legacy: HOPE ADVANCEs to EMPA-REG and LEADER: A Surprising similarity
Recently reported cardiovascular outcome studies on empagliflozin (EMPA-REG) and liraglutide (LEADER) have spurred interest in this field of diabetology. This commentary compares and contrasts these studies with two equally important outcome trials conducted using blood pressure lowering agents. A c...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Medknow Publications & Media Pvt Ltd
2017
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5240071/ https://www.ncbi.nlm.nih.gov/pubmed/28217527 http://dx.doi.org/10.4103/2230-8210.194341 |